Impact of removing ESBL status labelling from culture reports on the use of carbapenems for non-bacteraemic patients diagnosed with ESBL-positive urinary tract infections
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae135 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Lourdes R Menendez Alvarado und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Baptist Health South Florida, 1500 San Remo Ave, Miami, FL 33146, USA. Hauptthemen laut MEDLINE: Carbapenems, Urinary Tract Infections, Anti-Bacterial Agents, beta-Lactamases. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Objectives
To evaluate carbapenem prescribing rates for initial definitive treatment of urinary tract infections and clinical outcomes before and after removing ESBL status labels on antibiotic susceptibility reports.
Methods
This was a retrospective cohort study of adult patients treated for at least 48 h for an ESBL-producing/ceftriaxone-resistant Enterobacterales urinary tract infection. ESBL status reporting ceased in September 2022 for a network of seven community hospitals within the USA. The primary endpoint was the rate of carbapenem prescribing for initial definitive treatment of urinary tract infections. Secondary endpoints included total days of therapy for initial definitive treatment with carbapenems, clinical cure rates, time to transition to oral antibiotic therapy for initial definitive treatment, rate of guideline-compliant therapy, rate of relapsed infection within 30 days, 30 day readmission rate, and 30 day all-cause in-hospital mortality.
Results
Of 3055 patients screened, 199 were included in the pre group and 153 were included in the post group. The rate of carbapenem prescribing for initial definitive treatment was 156 patients (78%) in the pre group, compared with 93 patients (61%) in the post group (P = <0.01). Days of therapy for initial definitive therapy with carbapenem was 620 in the pre group compared with 372 in the post group (P < 0.01). There was no difference between other secondary outcomes.
Conclusions
Removing ESBL status labels from laboratory reports reduced carbapenem use for initial definitive treatment of urinary tract infections from 78% to 61% (P < 0.01) without impacting clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmacy Department, Baptist Health South Florida, 1500 San Remo Ave, Miami, FL 33146, USA.
- Center for Advanced Analytics, Baptist Health South Florida, 1500 San Remo Ave, Miami, FL 33146, USA.
ORCID-Profile: Lourdes R Menendez Alvarado
Zitieren
APA
Menendez Alvarado, L. R., Margulis Landayan, A., Williams, K. N., Frederick, C. M., Zhang, Z., & Gauthier, T. P. (2024). Impact of removing ESBL status labelling from culture reports on the use of carbapenems for non-bacteraemic patients diagnosed with ESBL-positive urinary tract infections. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae135
Vancouver
Menendez Alvarado LR, Margulis Landayan A, Williams KN, Frederick CM, Zhang Z, Gauthier TP. Impact of removing ESBL status labelling from culture reports on the use of carbapenems for non-bacteraemic patients diagnosed with ESBL-positive urinary tract infections. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae135
BibTeX
@article{MenendezAlvarado2024,
author = {Menendez Alvarado, Lourdes R and Margulis Landayan, Alice and Williams, Kelsey N and Frederick, Corey M and Zhang, Zhenwei and Gauthier, Timothy P},
title = {Impact of removing ESBL status labelling from culture reports on the use of carbapenems for non-bacteraemic patients diagnosed with ESBL-positive urinary tract infections},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae135}
}
EUVIMED